1. Home
  2. Labeler Index
  3. Qilu Pharmaceutical Co., Ltd.
  4. 67184-0574
  5. NDC Package Code: 67184-0574-1 Ganirelix Acetate

NDC Package 67184-0574-1 Ganirelix Acetate

Injection, Solution Subcutaneous - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
67184-0574-1
Package Description:
1 BLISTER PACK in 1 CARTON / 1 SYRINGE, GLASS in 1 BLISTER PACK / 1 mL in 1 SYRINGE, GLASS
Product Code:
67184-0574
Proprietary Name:
Ganirelix Acetate
Non-Proprietary Name:
Ganirelix Acetate
Substance Name:
Ganirelix Acetate
Usage Information:
Ganirelix Acetate Injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
11-Digit NDC Billing Format:
67184057401
NDC to RxNorm Crosswalk:
  • RxCUI: 855200 - ganirelix acetate 250 MCG in 0.5 ML Prefilled Syringe
  • RxCUI: 855200 - 0.5 ML ganirelix acetate 0.5 MG/ML Prefilled Syringe
  • RxCUI: 855200 - ganirelix acetate 0.5 MG/ML 0.5 ML Prefilled Syringe
  • RxCUI: 855200 - ganirelix acetate 250 MCG per 0.5 ML Prefilled Syringe
Product Type:
Human Prescription Drug
Labeler Name:
Qilu Pharmaceutical Co., Ltd.
Dosage Form:
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route(s):
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s):
GANIRELIX ACETATE 250 ug/.5mL
Pharmacologic Class(es):
Sample Package:
No
FDA Application Number:
ANDA218855
Marketing Category:
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date:
05-15-2025
Listing Expiration Date:
12-31-2026
Exclude Flag:
N
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 67184-0574-1?

The NDC Packaged Code 67184-0574-1 is assigned to a package of 1 blister pack in 1 carton / 1 syringe, glass in 1 blister pack / 1 ml in 1 syringe, glass of Ganirelix Acetate, a human prescription drug labeled by Qilu Pharmaceutical Co., Ltd.. The product's dosage form is injection, solution and is administered via subcutaneous form.

Is NDC 67184-0574 included in the NDC Directory?

Yes, Ganirelix Acetate with product code 67184-0574 is active and included in the NDC Directory. The product was first marketed by Qilu Pharmaceutical Co., Ltd. on May 15, 2025 and its listing in the NDC Directory is set to expire on December 31, 2026 if the product is not updated or renewed by the manufacturer.

What is the 11-digit format for NDC 67184-0574-1?

The 11-digit format is 67184057401. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-4-1 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-4-167184-0574-15-4-267184-0574-01